Last updated: February 21, 2026
What is NDC 00113-0622?
NDC 00113-0622 is the National Drug Code for Liraglutide (Victoza), a GLP-1 receptor agonist used primarily for type 2 diabetes management and weight loss.
Market Overview
Current Market Size and Usage
- Global Diabetes Market: Estimated at USD 86 billion in 2022, with a compound annual growth rate (CAGR) of 8.2% from 2023 to 2028 [1].
- Liraglutide Market Share: Victoza held approximately 48% of the GLP-1 receptor agonists market in the U.S. as of 2022 [2].
- Prescriptions (U.S.): In 2022, over 2.3 million prescriptions for Victoza were dispensed, reflecting active adoption [3].
Competitive Landscape
- Major competitors include: Semaglutide (Ozempic, Wegovy), Dulaglutide (Trulicity), Lixisenatide (Adlyxin).
- Innovator drugs like semaglutide are gaining share due to once-weekly dosing advantages.
- Patent expiry for Victoza is not expected until late 2020s, maintaining its market presence.
Regulatory Environment
- Approved for both diabetes and weight management in various countries.
- Recently, more formulations combining GLP-1 with other agents are entering the market, increasing competition.
Price Projections
Current Pricing (U.S.)
- Average Wholesale Price (AWP) for Victoza 1.8 mg per dose approximates USD 700-750.
- Cash Price for uninsured patients: USD 890-950 per 30-day supply.
- Insurance Reimbursements: Typically USD 10-50 co-pay after discounts.
Historical Price Trends
| Year |
Average Price per Dose |
Notes |
| 2018 |
USD 650 |
Launch year, prices stabilize |
| 2020 |
USD 715 |
Slight increase owing to inflation and demand |
| 2022 |
USD 720 – 750 |
Prices plateaued, competition emerges |
Short-term Projections (Next 3 Years)
- Stable Pricing: Due to lack of biosimilar competition until late 2020s.
- Potential Decrease: Slight decrease of 3-5%, driven by patent challenges or increased competition, especially from biosimilars if approved.
- Impact of New Formulations: Fixed-dose combinations may command premium pricing, maintaining or increasing profitability.
Long-term Projections (Next 5-10 Years)
- Biosimilar Entry: Possible generic or biosimilar options could reduce prices by 20-40% once patent protections expire.
- Market Penetration of Alternatives: Drugs like semaglutide may lead to a 15-25% reduction in Victoza's market share and prices.
- Pricing Strategy: Manufacturers may maintain premium pricing through formulation improvements or expanded indications.
Pricing Comparison with Competitors
| Drug |
Dosing Frequency |
Price Range (U.S.) |
Market Share (2022) |
Indications |
| Victoza (Liraglutide) |
Once daily |
USD 700–750 |
48% (GLP-1 market) |
Diabetes, weight loss |
| Ozempic (Semaglutide) |
Once weekly |
USD 850–900 |
35% |
Diabetes |
| Trulicity (Dulaglutide) |
Once weekly |
USD 750–800 |
10% |
Diabetes |
Price Sensitivity and Market Dynamics
- Premium Positioning: Victoza commands higher prices relative to older therapies (e.g., metformin).
- Cost-Effectiveness: Increasing evidence supports GLP-1 therapies for cardiovascular risk reduction, which can influence payer reimbursement.
- Form Drug Pricing Policies: Payers increasingly negotiate rebates and discounts, influencing real transaction prices.
Regulatory and Patent Considerations
- Patent protections for Victoza cover formulation and manufacturing processes until approximately 2024–2027.
- Patent challenges may lead to biosimilar entries, possibly reducing prices post-expiry.
Key Takeaways
- The current U.S. market price for Victoza remains stable, with slight upward trends in list prices.
- Competition from semaglutide and biosimilars could drive prices downward from 2025 onward.
- Market share consolidation is ongoing, with Victoza maintaining relevance through expanded indications.
- Pricing strategies aimed at payer negotiations and value demonstration are critical in maintaining profitability.
FAQs
1. When might biosimilar versions of Victoza enter the market?
Biosimilar approvals are anticipated around 2024–2025, contingent on patent litigation and regulatory pathways.
2. How do prices of Victoza compare globally?
Prices vary: Europe generally has lower list prices (~USD 495–550/month), influenced by national pricing policies and healthcare systems.
3. Will new formulations impact Victoza’s price?
Yes, fixed-dose combinations and once-weekly options may command higher prices, benefitting from convenience and improved adherence.
4. How significant is the impact of competition from semaglutide?
Semaglutide's once-weekly dosing and additional indications have led to increased market share and pricing pressure on Victoza.
5. What are the primary factors affecting future pricing?
Patent expiry, regulatory approvals for biosimilars, clinical evidence, payer negotiations, and market demand will shape future prices.
Sources:
[1] MarketWatch. (2022). Global Diabetes Market Report.
[2] IQVIA. (2022). U.S. Prescription Data for GLP-1 Receptor Agonists.
[3] SSR Health. (2022). U.S. Prescription Pricing & Trends.
[4] EvaluatePharma. (2023). Drug Pricing and Market Access Analysis.
